SECOND AMENDMENT TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • September 28th, 2012 • Neogenix Oncology Inc • In vitro & in vivo diagnostic substances
THIS SECOND AMENDMENT TO ASSET PURCHASE AGREEMENT (this “Amendment”) is entered into as of this 20th day of September 2012 by and between Precision Biologics, Inc., a Delaware corporation (“Purchaser”), and Neogenix Oncology, Inc., a Maryland corporation (“Seller”), and amends the Asset Purchase Agreement dated July 23, 2012 by and between Purchaser and Seller (the “Original Purchase Agreement”), as amended by the Amendment to Asset Purchase Agreement dated August 31, 2012 (the Original Purchase Agreement, as so amended, the “Purchase Agreement”). Terms defined in the Purchase Agreement and not otherwise defined herein are used herein as defined in the Purchase Agreement.
